Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gatifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.98 |
| ▸ | HPGD | P15428 | 6/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | POLB | P06746 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | CLK2 | P49760 | 1/20 | 0.98 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Gatifloxacin SCHEMBL1380257 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL982406 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL29765369 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL4818151 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL4818160 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL1046589 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL1380256 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL3565686 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (R)-Gatifloxacin SCHEMBL5670068 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL30910969 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396839-B2 | Crystalline forms of gatifloxacin | TEVA PHARMACEUTICALS USA, INC. (US) | 2008-07-08 | — | — | US | claimed |
| US-20060252772-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-11-09 | — | — | US | claimed |
| US-20060247255-A1 | Method for preparing a stable gatifloxacin composition | PATEL SATISHKUMAR A | 2006-11-02 | — | — | US | claimed |
| CN-1688310-A | Novel crystalline forms of gatifloxacin | TEVA PHARMA (IL) | 2005-10-26 | — | — | CN | claimed |
| CN-1665504-A | Novel crystalline forms of gatifloxacin | TEVA PHARMA (IL) | 2005-09-07 | — | — | CN | claimed |
| EP-1545530-A1 | NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN | Teva Pharmaceutical Industries Limited (IL) | 2005-06-29 | — | — | EP | claimed |
| EP-1485097-A1 | CRYSTALLINE FORMS OF GATIFLOXACIN AND PROCESSES FOR PREPARATION | Teva Pharmaceutical Industries Limited (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2004101547-A1 | PURIFICATION METHODS OF GATIFLOXACIN AND A NOVEL FORM OF GATIFLOXACIN | HETERO DRUGS LIMITED (IN) | 2004-11-25 | — | — | WO | claimed |
| US-20040192700-A1 | Novel crystalline forms of gatifloxacin | TEVA PHARMACEUTICALS USA, INC. | 2004-09-30 | — | — | US | claimed |
| US-20040171621-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | TEVA PHARMACEUTICALS USA, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004054583-A1 | CRYSTALLINE FORMS OF GATIFLOXACIN AND PROCESSES FOR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-07-01 | — | — | WO | claimed |
| WO-2004012739-A1 | NOVEL CRYSTALLINE FORMS OF GATIFLOXACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-12 | — | — | WO | claimed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| US-7781585-B2 | A crystalline form X, Y, Z of Gatifloxacindissolving gatifloxacin in methanol, removing insoluble, adding a base ( triethylamine or diisopropylethylamine), maintaining the reaction mixture at an appropriate temperature, cooling, isolating and drying; bactericides | MATRIX LABORATORIES LTD (IN) | 2010-08-24 | — | — | US | disclosed |
| US-20080199537-A1 | TOPICAL GATIFLOXACIN FORMULATIONS | ALCON RESEARCH, LTD. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7396839-B2 | Crystalline forms of gatifloxacin | TEVA PHARMACEUTICALS USA, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1326612-A1 | GATIFLOXACIN PENTAHYDRATE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6413969-B1 | HIGHLY HOMOGENEOUS FORM; STABLE PHARMACEUTICAL DOSAGE FORMS, INCLUDING AN AQUEOUS SUSPENSION | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020052379-A1 | Gatifloxacin pentahydrate | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-05-02 | — | — | US | disclosed |
| WO-2002022126-A1 | GATIFLOXACIN PENTAHYDRATE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192700-A1 | Novel crystalline forms of gatifloxacin | GATD3, SFPQ, RECQL | KDM4E 2124/4885ALDH1A1 4549/4885HPGD 4403/4885 |
| US-20020052379-A1 | Gatifloxacin pentahydrate | GATD3, CYP2F1, TCOF1 | KDM4E 3029/4885ALDH1A1 1013/4885HPGD 928/4885 |
| US-20060252772-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | GATD3, CRYAB, CRYZ | KDM4E 1732/4885ALDH1A1 4658/4885HPGD 2478/4885 |
| US-20040171621-A1 | Novel crystalline forms of gatifloxacin and processes for preparation | GATD3, CRYAB, CRYZ | KDM4E 1732/4885ALDH1A1 4658/4885HPGD 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.